BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19930611)

  • 41. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
    Møller MB; Christensen BE; Pedersen NT
    Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology.
    Martín-Moro F; Piris-Villaespesa M; Marquet-Palomanes J; García-Cosío M; Villarrubia J; Lario A; García I; Michael B; Roldán E; García-Vela JA; Lopez-Jiménez J
    Cytometry B Clin Cytom; 2020 Nov; 98(6):525-528. PubMed ID: 31873987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
    Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS
    J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.
    Chung R; Lai R; Wei P; Lee J; Hanson J; Belch AR; Turner AR; Reiman T
    Blood; 2007 Aug; 110(4):1278-82. PubMed ID: 17475910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
    Skacel M; Ross CW; Hsi ED
    Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Loss of 5-hydroxymethylcytosine as a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.
    Shen Y; Wang L; Ou J; Wang B; Cen X
    Int J Med Sci; 2022; 19(2):225-232. PubMed ID: 35165508
    [No Abstract]   [Full Text] [Related]  

  • 48. [Expression and clinical significance of CD40 in diffuse large B-cell lymphoma].
    Wang S; Wang YP; Hao YY; Zheng Y
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):819-23. PubMed ID: 24507100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry.
    Tomita N; Takeuchi K; Hyo R; Hashimoto C; Takemura S; Taguchi J; Fujita H; Fujisawa S; Ogawa K; Motomura S; Ishigatsubo Y
    Acta Haematol; 2009; 121(4):196-201. PubMed ID: 19468204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells.
    Tadmor T; Fell R; Polliack A; Attias D
    Hematol Oncol; 2013 Jun; 31(2):65-71. PubMed ID: 22714941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The clinical characteristics and prognostic analysis of 147 cases of diffuse large B-cell lymphoma].
    Zhao Q; Fu WJ; Zhang CY; Du J; Xi H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):737-40. PubMed ID: 24103868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
    Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
    Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
    Troppan KT; Schlick K; Deutsch A; Melchardt T; Egle A; Stojakovic T; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Pichler M
    Br J Cancer; 2014 Jul; 111(1):55-60. PubMed ID: 24874478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
    Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
    Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Diagnostic and prognostic values of flow cytometry in diffuse large B-cell lymphoma with bone marrow involvement].
    Hong Y; Wan WL; Li M; Wang H; Dong F; Jing HM; Ke XY; Zhu MX
    Zhonghua Yi Xue Za Zhi; 2023 Aug; 103(29):2258-2265. PubMed ID: 37544763
    [No Abstract]   [Full Text] [Related]  

  • 57. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
    Barrans SL; Carter I; Owen RG; Davies FE; Patmore RD; Haynes AP; Morgan GJ; Jack AS
    Blood; 2002 Feb; 99(4):1136-43. PubMed ID: 11830458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.